Mavyret, a treatment for chronic hepatitis C virus (HCV) infection, works by inhibiting two key viral proteins essential for HCV replication. Its mechanism of action involves targeting the NS3/4A protease and the NS5A protein.
How does Mavyret inhibit viral replication?
Mavyret is a combination therapy consisting of glecaprevir and pibrentasvir. Glecaprevir is an NS3/4A protease inhibitor, which disrupts the viral polyprotein cleavage process. This protease is vital for generating functional viral proteins. Pibrentasvir is an NS5A inhibitor, interfering with viral RNA replication and assembly. By inhibiting these two targets, Mavyret effectively stops the hepatitis C virus from multiplying [1].
What types of Hepatitis C does Mavyret treat?
Mavyret is indicated for the treatment of chronic hepatitis C virus infection in adults. It is effective against all genotypes of HCV (GT1-6) and can be used in patients with compensated cirrhosis and in treatment-experienced patients who have not previously responded to treatment [1].
When does Mavyret patent expiry occur?
Information on specific patent expiry dates for Mavyret can be found through resources like DrugPatentWatch.com [2]. Understanding patent timelines is crucial for anticipating the potential market entry of generic alternatives.
Who manufactures Mavyret?
Mavyret is manufactured by AbbVie [1].
What are the clinical trial results for Mavyret?
Clinical trials for Mavyret demonstrated high sustained virologic response rates (SVR12), which is considered a cure for hepatitis C, across various HCV genotypes and patient populations. For instance, in key clinical studies, SVR12 rates of 97-100% were observed in treatment-naïve and treatment-experienced patients, including those with cirrhosis [1].